COSVATE SOR OINT
₹713.57
Cosvate Sor Ointment is a topical medication combining Clobetasol Propionate (0.05%) and Calcipotriol (0.005%), used primarily for the treatment of plaque psoriasis. Clobetasol is a potent corticosteroid that reduces inflammation, while Calcipotriol, a vitamin D analogue, helps regulate skin cell production. Together, they alleviate symptoms like redness, scaling, and itching associated with psoriasis.
Description
Composition
-
Clobetasol Propionate (0.05%): A high-potency corticosteroid that suppresses inflammation, redness, and itching by inhibiting the release of inflammatory substances in the skin.
-
Calcipotriol (0.005%): A synthetic form of vitamin D that slows down the excessive skin cell growth characteristic of psoriasis, promoting normal skin development.
Indications
Cosvate Sor Ointment is indicated for the topical treatment of plaque psoriasis, a chronic skin condition characterized by red, scaly patches. It helps in reducing the severity of lesions and provides symptomatic relief.
Usage Instructions
-
Application: Apply a thin layer of the ointment to the affected area once daily. Gently rub in until fully absorbed.
-
Duration: Use for up to 2 weeks or as directed by your healthcare provider.
-
Precautions:
-
For external use only.
-
Avoid application on the face, groin, or underarms unless prescribed.
-
Do not cover the treated area with airtight dressings unless advised by a doctor.
-
Wash hands thoroughly after application.
-
Avoid contact with eyes, mouth, and mucous membranes.
-
Side Effects
Common side effects may include:
-
Itching
-
Rash
-
Skin irritation
If any of these effects persist or worsen, consult your healthcare provider promptly.
Precautions
-
Pregnancy: Use only if clearly needed and prescribed by a doctor.
-
Breastfeeding: Likely safe; however, avoid application on the breast area to prevent ingestion by the infant.
-
Children: Safety and efficacy in pediatric patients have not been established; use only under medical supervision.
Reviews
There are no reviews yet.